Skip to main content
. 2020 May 22;10:8537. doi: 10.1038/s41598-020-65250-3

Figure 4.

Figure 4

ERK isoforms have opposite effects on lung metastatic burden. (A) copGFP-labeled SUM149 SCR, shERK1, and shERK2 cells were generated, and ERK isoform knockdown was confirmed by immunoblotting. (B,C) Nine weeks after cancer cell injection, mice were sacrificed, lung metastatic burden was observed using stereomicroscopy, and total tumor area was quantified. ERK1 knockdown dramatically increased metastatic burden. ERK2 knockdown almost entirely prevented lung metastasis. (D) Micrographs (20X) of lung SUM149 SCR and SUM149 shERK1 tumors immunohistochemically stained for hematoxylin and eosin, proliferation marker Ki67, ERK, and phosphorylated ERK. (E) Kaplan-Meier survival analysis shows that mice bearing SUM149 shERK2 tumors survived longer than control mice or mice bearing SUM149 shERK1 tumors. No tumor tissue was identified in the lungs of mice injected with shERK2 40-44 cells.